Polycystic Ovarian Syndrome (PCOS) and Hormonal Imbalances

Hair Loss and Hormonal Imbalance in Women

Expert advice, tips, and treatments for hair thinning caused by PCOS and hormonal changes.

Understanding Female Hair Loss

Female hair loss often presents as diffuse thinning across the scalp, particularly at the crown and vertex. Unlike male pattern baldness, complete bald patches are uncommon. Hormonal imbalance, especially in conditions like PCOS, is a leading cause.

How PCOS Affects Hair

  • Hyperandrogenism: High androgen levels shorten the growth (anagen) phase and miniaturize hair follicles, causing thinning.
  • Insulin resistance: Common in PCOS, it increases ovarian androgen production and worsens hair loss.
  • Inflammation: Low-grade systemic inflammation can weaken hair follicles and exacerbate shedding.

Other Hormonal Imbalances

  • Thyroid disorders: Hypothyroidism or hyperthyroidism disrupt hair follicle cycles.
  • Prolactin excess: Can inhibit hair follicle activity.
  • Estrogen and progesterone drops: Postpartum or perimenopausal changes reduce hair support.
  • Other androgen excess: Congenital adrenal hyperplasia or tumors may cause thinning similar to PCOS.

Signs and Symptoms

  • Gradual thinning at the crown and vertex
  • Increased hair shedding
  • Accompanying signs of hyperandrogenism: acne, hirsutism, irregular periods

Diagnosis

A thorough evaluation is essential and typically includes:

  • Medical history and medication review
  • Physical exam and hair density assessment
  • Blood tests: testosterone, DHEAS, LH/FSH ratio, thyroid function, prolactin, fasting glucose/insulin
  • Pelvic ultrasound for ovarian morphology

Treatment Options

  • Lifestyle: Weight management, exercise, and low-glycemic diet to improve insulin sensitivity.
  • Medications: Anti-androgens (spironolactone, finasteride), oral contraceptives, and topical minoxidil.
  • Supplements & therapies: Iron, vitamin D, biotin, zinc, PRP, or low-level laser therapy in selected cases.

Prognosis

Early detection and targeted therapy can stabilise hair loss and promote regrowth. Genetic predisposition and chronic hormonal imbalance may limit full restoration, but most women experience noticeable improvement with proper management.

References

  • Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
  • Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.
  • Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14:270–284.
  • Hordinsky MK. Female pattern hair loss. Dermatol Clin. 2018;36(1):35–41.
  • Ramos PM, Miot HA. Female pattern hair loss: a clinical and pathophysiological review. An Bras Dermatol. 2015;90(1):62–69.
  • Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520.

A/Prof Niloufar Torkamani is a leading endocrinologist specialising in hair loss and hormonal disorders in women and men. She integrates advanced endocrine care with the latest therapies for hair restoration, including treatments targeting androgenic alopecia, hormonal imbalance, and PCOS-related hair thinning. She combines clinical expertise with evidence-based innovation, guiding patients through tailored medical solutions that optimize hair growth and overall health. A/Prof Torkamani is also involved in international research and education, promoting awareness and effective management strategies for hair loss as part of endocrine health.